Immupel evolved as a more advanced alginate capsule for xeno-transplantation of mature cells. That's its primary purpose and design.
Its unlikely to be of any benefit in stem cells research. The requirements are entirely different.
If that's the focus of this director change proposal, then it needs to be clearly stated so every body understands what is being planned by this group.
Pacific Channel releases updated internal analysis of LCT 10/09/2019, page-38
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.49M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 0.9¢ | 0.8¢ | $17.46K | 2.182M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 4501358 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 2830688 | 15 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |